







an Open Access Journal by MDPI

# The Role of Cytoreductive Surgery in Cancers

Guest Editor:

#### **Dr. Andreas Bremers**

Department of Surgery, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands

Deadline for manuscript submissions:

31 July 2024

### Message from the Guest Editor

Dear Colleagues,

This Special Issue "The Role of Cytoreductive Surgery in Cancers" explores the significance and impact of cytoreductive surgery on various types of cancer. This collection of articles delves into this surgical approach and its outcomes. It focuses on the role of cytoreduction in improving the survival rates, reducing the tumor burden, and enhancing the effectiveness of other treatment modalities, such as chemotherapy and radiation therapy. We also discuss the challenges and limitations associated with cytoreductive surgery, as well as the potential strategies employed to overcome them. Overall, this Special Issue provides valuable insights into the evolving field of cytoreductive surgery and its potential to revolutionize cancer treatment by targeting the primary tumor site and minimizing the risk of metastasis.

Dr. Andreas Bremers *Guest Editor* 













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**